In patients with mild chronic hepatitis C (CHC), body mass index (BMI) <24 and liver stiffness measures (LSM) <5.9, the likelihood of cirrhosis progression is very low, allowing for a significant spacing of noninvasive assessments over time. Researchers evaluated the usefulness of consecutive LSM, APRI, FIB-4 and Forns scores to predict disease progression in areas with limited access to antiviral therapy. Patients with CHC and at least 2 annual LSM within 3 years were followed for a minimum of 5 years. Noninvasive scores were assessed. They found:
- 623 non-cirrhotic patients were included.
- Median baseline LSM was 6.6 kPa.
- During a median follow-up of 6 years, 61 (9.7%) patients developed cirrhosis.
- Baseline LSM and Forns were highly predictive of cirrhosis development.
- Baseline BMI ≥24 kg/m2 and LSM ≥5.0 kPa were associated to progression.
Lens S, Torres F, Bonacci M, et al. Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. [Published online ahead of print November 29, 2018]. Dig Liver Dis. doi:10.1016/j.dld.2018.11.019.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al